Literature DB >> 34019285

Biophysical and Structural Methods to Study the bHLHZip Region of Human c-MYC.

Giovanna Zinzalla1.   

Abstract

The C-terminal region of the c-MYC transcription factor consists of approximately 100 amino acids that in its native state does not adopt a stable structure. When this region binds to the obligatory partner MAX via a coupled folding-and-binding mechanism, it forms a basic-helix-loop-helix-leucine zipper (bHLHZip) heterodimeric complex. The C-terminal region of MYC is the target for numerous drug discovery programs for direct MYC inhibition via blocking the dimerization event and/or binding to DNA, and a proper understanding of the partially folded, dynamic nature of the heterodimeric complex is essential to these efforts. The bHLHZip motif also drives protein-protein interactions with cofactors that are crucial for both transcriptional repression and activation of MYC target genes. Targeting these interactions could potentially provide a means of developing alternative approaches to halt MYC functions; however, the molecular mechanism of these regulatory interactions is poorly understood. Herein we provide methods to produce high-quality human c-MYC C-terminal by itself and in complex MAX, and how to study them using Nuclear Magnetic Resonance spectroscopy and X-ray crystallography. Our protein expression and purification protocols have already been used to study interactions with cofactors.

Entities:  

Keywords:  Cofactors; DNA binding; Heterodimerization; Intrinsically disorder regions; MAX; MYC; NMR; Protein–protein interactions; X-ray crystallography; bHLHZip

Year:  2021        PMID: 34019285     DOI: 10.1007/978-1-0716-1476-1_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  24 in total

1.  Unmasking the Mysteries of MYC.

Authors:  Rajeev M Nepal; Alberto Martin
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

Review 2.  Therapeutic strategies to inhibit MYC.

Authors:  Michael R McKeown; James E Bradner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

Review 3.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

4.  Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy.

Authors:  Julie A Wolfram; Edward J Lesnefsky; Brian D Hoit; Mark A Smith; Hyoung-Gon Lee
Journal:  Ther Adv Chronic Dis       Date:  2011-03-01       Impact factor: 5.091

Review 5.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

6.  Endogenous Myc maintains the tumor microenvironment.

Authors:  Nicole M Sodir; Lamorna Brown Swigart; Anthony N Karnezis; Douglas Hanahan; Gerard I Evan; Laura Soucek
Journal:  Genes Dev       Date:  2011-04-08       Impact factor: 11.361

Review 7.  MYC activation is a hallmark of cancer initiation and maintenance.

Authors:  Meital Gabay; Yulin Li; Dean W Felsher
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 8.  The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis.

Authors:  Patrick A Carroll; Brian W Freie; Haritha Mathsyaraja; Robert N Eisenman
Journal:  Front Med       Date:  2018-07-27       Impact factor: 4.592

Review 9.  Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.

Authors:  Brittany L Allen-Petersen; Rosalie C Sears
Journal:  BioDrugs       Date:  2019-10       Impact factor: 5.807

10.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Authors:  Roderik M Kortlever; Nicole M Sodir; Catherine H Wilson; Deborah L Burkhart; Luca Pellegrinet; Lamorna Brown Swigart; Trevor D Littlewood; Gerard I Evan
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.